Published in Oncotarget on December 01, 2012
Immunosuppressants in cancer prevention and therapy. Oncoimmunology (2013) 1.17
Rejuvenating immunity: "anti-aging drug today" eight years later. Oncotarget (2015) 1.13
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget (2014) 1.08
Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget (2014) 1.05
Signaling pathways activation profiles make better markers of cancer than expression of individual genes. Oncotarget (2014) 1.05
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis (2013) 1.04
Metformin: do we finally have an anti-aging drug? Cell Cycle (2013) 0.98
Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget (2015) 0.94
Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget (2014) 0.93
Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann Transl Med (2014) 0.93
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget (2014) 0.92
Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget (2015) 0.92
Targeting nucleocytoplasmic transport in cancer therapy. Oncotarget (2014) 0.88
Comparison of rapamycin schedules in mice on high-fat diet. Cell Cycle (2014) 0.87
Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. Cell Cycle (2014) 0.86
Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion. Oncotarget (2015) 0.86
Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. Oncotarget (2015) 0.86
Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle (2014) 0.85
Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis. Oncotarget (2015) 0.81
Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins. Aging (Albany NY) (2014) 0.79
Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget (2015) 0.78
Ubiquitous transgenic overexpression of C-C chemokine ligand 2: a model to assess the combined effect of high energy intake and continuous low-grade inflammation. Mediators Inflamm (2013) 0.78
Age-related obesity and type 2 diabetes dysregulate neuronal associated genes and proteins in humans. Oncotarget (2015) 0.78
Minoxidil may suppress androgen receptor-related functions. Oncotarget (2014) 0.78
Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy. Oncotarget (2014) 0.77
Protein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN). Cell Cycle (2014) 0.77
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. Oncotarget (2016) 0.77
The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget (2015) 0.76
Polyphenolic drug composition based on benzenepolycarboxylic acids (BP-C3) increases life span and inhibits spontaneous tumorigenesis in female SHR mice. Aging (Albany NY) (2016) 0.75
From rapalogs to anti-aging formula. Oncotarget (2017) 0.75
Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling. PLoS One (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 19.56
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Extending healthy life span--from yeast to humans. Science (2010) 12.12
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science (2005) 11.31
Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol (2004) 9.96
Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A (2001) 7.93
Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med (2005) 7.83
Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science (2009) 7.80
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol (2009) 7.74
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
Genetics: influence of TOR kinase on lifespan in C. elegans. Nature (2003) 7.55
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (2007) 7.11
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev (2006) 6.62
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci (2010) 5.54
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature (1997) 5.43
Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle (2011) 5.42
The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development (2004) 5.27
Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature (2012) 5.00
Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A (2004) 4.60
Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab (2010) 4.44
With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab (2010) 4.11
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Rapamycin decelerates cellular senescence. Cell Cycle (2009) 3.97
mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal (2009) 3.94
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A (2010) 3.81
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature (2010) 3.81
Rapamycin slows aging in mice. Aging Cell (2012) 3.76
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle (2008) 3.37
Weak p53 permits senescence during cell cycle arrest. Cell Cycle (2010) 3.33
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A (2008) 3.30
Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics (2011) 3.28
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst (2009) 3.15
Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci U S A (1995) 3.08
Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov (2012) 3.02
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol (2011) 2.99
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell (2012) 2.96
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
Pseudo-DNA damage response in senescent cells. Cell Cycle (2009) 2.93
Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle (2011) 2.92
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell (2009) 2.74
mTOR signaling in disease. Curr Opin Cell Biol (2011) 2.73
Caloric restriction in humans. Exp Gerontol (2007) 2.66
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget (2010) 2.64
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 2.61
Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) (2010) 2.60
Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) (2012) 2.59
Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med (2012) 2.58
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
Allele-specific p53 mutant reactivation. Cancer Cell (2012) 2.51
mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A (2008) 2.48
Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science (1995) 2.42
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol (2011) 2.40
Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med (2011) 2.33
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28
The naked mole-rat: a new long-living model for human aging research. J Gerontol A Biol Sci Med Sci (2005) 2.28
Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol (2010) 2.22
Antiangiogenic therapy and tumor progression. Cancer Cell (2004) 2.20
Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans. Nature (2008) 2.14
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
The critical role of metabolic pathways in aging. Diabetes (2012) 2.12
Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res (2005) 2.07
Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci (2012) 2.04
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle (2012) 2.00
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell (2012) 1.99
Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med (2012) 1.98
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) (2010) 1.97
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation (2005) 1.94
Big mice die young: early life body weight predicts longevity in genetically heterogeneous mice. Aging Cell (2002) 1.90
Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol (2011) 1.86
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle (2010) 1.85
Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst (2012) 1.84
Extension of chronological life span by reduced TOR signaling requires down-regulation of Sch9p and involves increased mitochondrial OXPHOS complex density. Aging (Albany NY) (2009) 1.82
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell (2012) 1.79
Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) (2012) 1.79
Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology (2012) 1.77
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res (2007) 1.76
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget (2011) 1.73
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle (2010) 1.73
Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med (2005) 1.72